Compare BAFN & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BAFN | ACOG |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 193.6M |
| IPO Year | 2021 | 2024 |
| Metric | BAFN | ACOG |
|---|---|---|
| Price | $5.47 | $9.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 127.7K | 98.1K |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.58 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,220,275.00 |
| Revenue This Year | N/A | $153.87 |
| Revenue Next Year | N/A | $85.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.26 | $4.50 |
| 52 Week High | $10.38 | $10.14 |
| Indicator | BAFN | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 32.64 | 50.32 |
| Support Level | $4.53 | $7.50 |
| Resistance Level | $6.75 | $9.17 |
| Average True Range (ATR) | 0.78 | 0.48 |
| MACD | -0.24 | 0.03 |
| Stochastic Oscillator | 0.00 | 55.75 |
BayFirst Financial Corp is a bank holding company that operates through its wholly owned subsidiary. The Company generates the majority of its revenue from interest on loans and noninterest income. The primary sources of funding for its loans are loan payments, deposits, and borrowings. It is dependent on noninterest income, which is derived from net gain on the sales of the guaranteed portion of government-guaranteed loans and service fee income. The company provides personal banking and business banking services.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.